Clinical Studies Sponsored by Exelixis

Clinical Studies where

Trial Sponsor

Name	NCT Number	Health Conditions in Trial	Clinical Trial Start Date	Study Completion Date	Clinical Trial Study Type
‌ A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors	NCT01100619	Renal cell carcinoma Papillary thyroid cancer Follicular thyroid cancer	2010		Interventional
‌ Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies	NCT00215605	Lymphoma Cancer	2005	2012	Interventional
‌ A Safety Study of XL019 in Adults With Myelofibrosis	NCT00522574	Polycythemia vera ‌ Myelofibrosis	2007		Interventional
‌ A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer	NCT00596648		2007		Interventional
‌ Study of XL281 in Adults With Solid Tumors	NCT00451880	Cancer Colorectal cancer Melanoma Papillary thyroid cancer	2007	2011	Interventional
‌ A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors	NCT06630247		2024	2027	Interventional
‌ Study of XB010 in Subjects With Solid Tumors	NCT06545331		August 6, 2024	October 20, 2027	Interventional
‌ A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib	NCT00570635		2007	2009	Interventional
‌ Study of XL418 in Adults With Solid Tumors	NCT00460278	Cancer	2007		Interventional
‌ Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia	NCT00234481				Interventional
‌ Study of XL820 Given Orally Daily to Subjects With Solid Tumors	NCT00350831	Cancer	2006		Interventional
‌ Expanded Access of Cabozantinib in Medullary Thyroid Cancer	NCT01683110	Medullary thyroid cancer
‌ Study of XL820 in Adults With Solid Tumors	NCT00129571	Cancer	2005		Interventional
‌ Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors	NCT00796484	Cancer	2008	2010	Interventional
‌ Study of Cabozantinib (XL184) in Adults With Advanced Malignancies	NCT00940225	Cancer	2009	2014	Interventional
‌ A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma	NCT01865747	Renal cell carcinoma	2013	January 15, 2021	Interventional
‌ Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma	NCT03937219	Renal cell carcinoma	June 25, 2019	2025	Interventional
‌ A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors	NCT03845166	Colorectal cancer Renal cell carcinoma	March 20, 2019	2024	Interventional
‌ Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies	NCT00526838	Lymphoma Cancer	2007	2010	Interventional
‌ Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)	NCT06191796		2024	2027	Interventional
‌ Study of XL114 in Subjects With Non-Hodgkin's Lymphoma	NCT05144347		April 12, 2022	November 1, 2022	Interventional
‌ A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer	NCT01896479	Medullary thyroid cancer	2014	2023	Interventional
‌ Study of XB002 in Subjects With Solid Tumors (JEWEL-101)	NCT04925284	Cervical cancer Pancreatic cancer Endometrial cancer	June 7, 2021	October 7, 2024	Interventional
‌ Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	NCT03170960	Colorectal cancer Hepatocellular carcinoma Endometrial cancer Renal cell carcinoma Ovarian cancer Head and neck cancer	September 5, 2017	2024	Interventional
‌ A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies	NCT00475917	Lymphoma Cancer	2007	2008	Interventional

Results per page:

36 results

0 selected

36 results

0 selected